|
Published by: SMI Publishing, Ltd
Published: Jun. 11, 2007
Table of Contents
- Day One
- 8.30 Registration & Coffee
- 9.00 Chairperson's Opening Remarks
- Dr Liza Leventhal, Principal Scientist 1, Wyeth Research.
- 9.10 TRPV1 AGONIST APPROACHES TO LOCALIZED MANAGEMENT OF CHRONIC PAIN
- A clinically validated therapeutic modality
- Bases of nociceptor overactivity
- Expression of TRPV1 in hyperactive nociceptors
- Agonist-induced desensitization
- Phase 2 clinical data for nociceptive pain
- Phase 3 clinical data for neuropathic pain
- Dr Keith Bley, Senior Vice President, Nonclinical R & D, Neurogesx Inc.
- 9.50 CANNABINOR, A CB2 SELECTIVE SYNTHETIC CANNABINOID AGONIST FOR THE TREATMENT OF CHRONIC PAIN
- CB2 receptors as drug targets for neuropathic and chronic pain
- Rational drug design of CB2 agonists
- CB receptor binding affinity and selectivity
- Pharmacological efficacy in animal models
- Pharmaceutical development
- Human trials with Cannabinor
- Dr Shimon Amselem, Vice President, Pharmaceutical Development, Pharmos Ltd..
- 10.30 Morning Coffee
- 11.00 NOVEL APPROACHES TO PAIN MEASUREMENTS IN RODENTS
- Beyond thresholds and latencies
- Brief overview of traditional methods for evaluating pain in preclinical models
- Introduction to alternative approaches for evaluating pain in preclinical models
- Review of studies evaluating gait analysis in preclinical pain models
- Alternative approaches and endpoints
- Future directions
- Dr Liza Leventhal, Principal Scientist 1, Wyeth Research.
- 11.40 SMALL MOLECULE INHIBITORS OF Kv1.X/Kvß CHANNEL SUBUNIT
- Kv channels as targets for the treatment of pain
- Kv1.x/Kvß LEPTICS® assay development and hit identification
- In vitro electrophysiological characterisation of novel inhibitors of
- Kv1.x/Kvß subunits in rat DRGs
- In vivo evaluation of novel inhibitors of Kv1.x/Kvß subunits in models
- of inflammatory and neuropathic hyperalgesia
- Roland Kozlowski, Chief Executive Officer , Lectus Therapeutics.
- 12.20 Networking Lunch
- 1.50 ENGAGING THE REGULATORY AUTHORITIES WITH EMERGING BIOMARKERS: NEW WHYS AND WAYS
- Increasing your leverage of Biomarkers in drug development
- Drivers for biomarkers in the industry
- Some working definitions and terms of engagement
- Application of biomarkers across the pipeline, from imaging to systemic biomarkers
- Biomarker-specific considerations with regulatory authorities in the US and EU
- Dr Linda Surh, Director, CEDD Global Regulatory Affairs , GlaxoSmithKline.
- 2.30 ION CHANNELS, CAN THEY PROVIDE NEW TARGETS FOR EFFECTIVE PAIN RELIEF?
- Voltage-gated sodium channels and what human genetic data tells us
- Calcium Channels; can we improve on Ziconotide?
- Ligand-gated channels; which are the most likely winners?
- Emerging ion channel targets
- Dr Steve England, Associate Research Fellow, Discovery Biology, Pfizer.
- 3.10 Afternoon Tea
- 3.40 THE PURINERGIC CASCADE AS TARGETS FOR PAIN TREATMENT
- The role of adenosine in pain: P1 receptors and adenosine modulation
- The role of P2X
- The role of P2Y
- Professor Theo Meert, Senior Research Fellow, Therapeutic Area Leader & Biology Head, CNS, Pain & Neurology, Johnson & Johnson .
- 4.20 SOME COMPELLING REASONS TO MEASURE MOODS DURING CHRONIC PAIN STUDIES
- Chronic pain makes people angry, sad, fatigued and irritable
- These moods can be measured more reliably than pain itself
- They are risk factors for cardiovascular events such as seen in the Vioxx study
- Pain may decrease but if these moods do not, the risks remain.
- Doing so improves: patient selection and compliance, dose efficacy monitoring, data variance & trial sensitivity
- It demonstrates a quality of life advantage for the product.
- Andrew Sutton, Medical Director, Guildford Clinical Pharmacology Ltd (GCPL).
- 5.00 Chairperson’s Closing Remarks and Close of Day One
- Day Two
- 8.30 Registration & Coffee
- 9.00 Chairman's Opening Remarks
- Dr James Sullivan, Divisional Vice President, Neuroscience Discovery, Abbott Laboratories.
- 9.10 CASE STUDY: ABBOTT’S NEURONAL NICOTINIC RECEPTOR PROGRAMME
- Dr James Sullivan, Divisional Vice President, Neuroscience Discovery, Abbott Laboratories.
- 9.50 ACTIVATING CHOLINERGIC NICOTINIC RECEPTORS, GROUNDBREAKING APPROACHES TO NEUROPATHIC PAIN
- Advances in the development of safer nicotinic agonists for the treatment of chronic pain conditions
- Inducing antinociception by the activation of nicotinic receptors by the endogenous neurotransmitter acetylcholine or exogenous agonists
- The efficacy of nicotinic agonists shown in preclinical models of inflammatory and neuropathic pain
- Suggestions of how this efficacy can be achieved in man
- The preclusion of prior further development due to poor margin of safety
- Achieving a better margin of safety by activating nicotinic receptors in the CNS without activating peripheral nicotinic receptors
- Dr Emanuele Sher, Research Advisor, Pain/Migraine Team, Eli Lilly & Company.
- 10.30 Morning Coffee
- 11.00 NOVEL APPROACHES TO INFLAMMATORY AND NEUROPATHIC PAIN
- Rationale for use of immunomodulatory agents (IMiDs®) in pain
- Preclinical pharmacology of thalidomide and lenalidomide
- Clinical studies in complex regional pain syndrome
- Implications for future research and therapeutics
- Dr Peter Schafer, Director, Biology, Drug Discovery, Celgene Corporation.
- 11.40 DEVELOPMENT AND VALIDATION OF A VOLUNTEER MODEL OF NEUROPATHIC PAIN
- What clinical end points are appropriate for healthy volunteers?
- selection of a model
- validation and bench-marking of a model
- Can a healthy volunteer model predict clinical efficacy?
- Dr John Connell, Director, Clinical Pharmacodynamics & Project Management, Icon Development Solutions.
- 12.20 Networking Lunch
- 1.50 TARGETING SIGMA RECEPTORS AS A NEW THERAPEUTIC STRATEGY FOR NEUROPATHIC PAIN
- How Sigma 1 receptor knockout mice do not develop allodynic behaviours after sciatic nerve lesions are induced
- Spinal cords from mice lacking Sigma 1 receptors show reduced wind-up amplification
- Neuropathic pain behaviours in wild-type animals are inhibited by new and selective Sigma 1 receptor antagonists
- Medicinal chemistry approaches for discovery and development of highly selective Sigma receptor ligands
- Dr Helmut Buschmann, Research Director, Laboratorios Dr. Esteve.
- 2.30 DEFINING THE ROLE OF MrgD IN PAIN
- Dr Edward Kaftan, Principal Research Scientist, Wyeth .
- 3.10 TRIPTANS IN THE MANAGEMENT OF MIGRAINES AND OTHER HEADACHE DISORDERS
- Extending the role of triptans in headache management
- Review of the pharmacology of triptans
- Review of recent data relevant to migraine management
- Efficacy and safety of the triptans in migraine treatment
- Menstrual migraine prevention with frovatriptan
- Triptans and management of other headaches
- John Hutchinson, Development Director and Board Member, Vernalis.
- Dr Stephen Pawsey, Director, Medical Affairs, Vernalis.
- 3.50 Chairman’s Closing Remarks and Close of Day Two
AbstractAs pharmaceutical companies continually strive to find new and evolving ways to combat neuropathic and neurological pain, The SMi Group’s 8th Annual Pain Therapeutics Conference once again showcases the new advances within the pharmaceutical industry.
Listen to case studies on novel targets for effective pain relief such as ion channels, CB2 receptors and the purinergic cascade and explore revolutionary strategies for confronting neuropathic pain.
Senior representatives from the top 10 Pharmaceutical Companies together with those from pharmaceutical companies that specialise in pain medication will deliver a series of specialised presentations detailing the discoveries and advances they have made over the last 12 months
The conference will be delivered by an excellent panel of speakers, including:
- Dr James Sullivan, Divisional Vice President, Neuroscience Discovery, Abbott Laboratories
- Dr Linda Surh, Director, CEDD Global Regulatory Affairs, GlaxoSmithKline
- Dr Keith Bley, Senior Vice President, Nonclinical R&D, NeurogesX Inc
- Dr Shimon Amselem, Vice President, Pharmaceutical Development, Pharmos Ltd
- Professor Theo Meert, Senior Research Fellow, Therapeutics Area Leader & Biology Head, CNS, Pain & Neurology, Johnson & Johnson
- Dr Liza Leventhal, Principal Research Scientist 1, Neuroscience Discovery Research, Wyeth
- Dr Steve England, Associate Research Fellow, Discovery Biology, Pfizer
- Dr John Connell, Director, Clinical Pharmacodynamics & Project Management, Icon Development Solutions
- Dr Emanuele Sher, Research Advisor, Pain/Migraine Team, Eli Lilly and Company
- Roland Kozlowski, Chief Executive Officer, Lectus Therapeutics
- Dr Edward Kaftan, Principal Research Scientist, Wyeth
- Dr Peter Schafer, Director, Biology, Drug Discovery, Celgene Corporation
- Dr John Hutchinson, Development Director and Board Member, Vernalis
- Dr Helmut Buschman, Research Director, Laboratorios Dr. Esteve
- Andrew Sutton, Medical Director, Guildford Clinical Pharmacology
Essential updates provided on:
- GROUNDBREAKING NEW TARGETS for effective pain relief
- SUCCESSFUL AND NOVEL approaches to neuropathic and neurological pain
- NEW AND EVOLVING ANALGESICS in development.
- THE RELEVANCE of translational pharmacology to neurological pain
- THE IMPORTANCE of animal pain models
The continual success of The SMi Group’s Pain Therapeutics Conference stands as proof of its reputation as the leading conference in the field. With this year's promising to be the most successful, attendance is compulsory in order to keep abreast of developments in this ever-evolving industry.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
